Immatics Announces Second Quarter 2024 Financial Results and Business Update
Immatics N.V. (NASDAQ: IMTX) reported its Q2 2024 financial results and provided a business update. Key highlights include:
- ACTengine® IMA203 targeting PRAME showed a 55% confirmed objective response rate in 30 metastatic melanoma patients, with a median duration of response of 13.5 months.
- First Phase 1 data from TCER® IMA401 (MAGEA4/8) to be presented at ESMO Congress 2024.
- Cash position of $568.5 million as of June 30, 2024, funding operations into 2027.
- Q2 2024 revenue was $20.1 million, with a net loss of $19.3 million.
- Appointment of Alise Reicin M.D. to Board of Directors.
Immatics N.V. (NASDAQ: IMTX) ha riportato i risultati finanziari del secondo trimestre del 2024 e fornito un aggiornamento aziendale. I principali punti salienti includono:
- ACTengine® IMA203 che mira a PRAME ha mostrato un tasso di risposta obiettiva confermata del 55% in 30 pazienti con melanoma metastatici, con una durata mediana della risposta di 13,5 mesi.
- I primi dati della Fase 1 da TCER® IMA401 (MAGEA4/8) saranno presentati al Congresso ESMO 2024.
- Una posizione di liquidità di 568,5 milioni di dollari al 30 giugno 2024, a sostegno delle operazioni fino al 2027.
- Nel secondo trimestre del 2024, i ricavi sono stati di 20,1 milioni di dollari, con una perdita netta di 19,3 milioni di dollari.
- Nomina di Alise Reicin M.D. nel Consiglio di Amministrazione.
Immatics N.V. (NASDAQ: IMTX) informó sus resultados financieros del segundo trimestre de 2024 y proporcionó una actualización comercial. Los puntos clave incluyen:
- ACTengine® IMA203 dirigido a PRAME mostró una tasa de respuesta objetiva confirmada del 55% en 30 pacientes con melanoma metastásico, con una duración media de respuesta de 13,5 meses.
- Se presentarán los primeros datos de la Fase 1 de TCER® IMA401 (MAGEA4/8) en el Congreso ESMO 2024.
- Una posición de efectivo de 568,5 millones de dólares al 30 de junio de 2024, financiando las operaciones hasta 2027.
- Los ingresos del segundo trimestre de 2024 fueron de 20,1 millones de dólares, con una pérdida neta de 19,3 millones de dólares.
- Nombramiento de Alise Reicin M.D. a la Junta Directiva.
Immatics N.V. (NASDAQ: IMTX)는 2024년 2분기 재무 결과를 발표하고 비즈니스 업데이트를 제공했습니다. 주요 내용은 다음과 같습니다:
- ACTengine® IMA203이 PRAME을 겨냥하여 30명의 전이성 악성 흑색종 환자에서 55%의 확인된 객관적 반응률을 보였으며, 반응의 중앙 지속 기간은 13.5개월이었습니다.
- TCER® IMA401 (MAGEA4/8)의 1상 데이터가 ESMO Congress 2024에서 발표될 예정입니다.
- 2024년 6월 30일 기준 현금 보유액은 5억 6,850만 달러로, 2027년까지 운영 자금을 지원합니다.
- 2024년 2분기 수익은 2,010만 달러였으며, 순손실은 1,930만 달러였습니다.
- Alise Reicin M.D.의 이사회 임명.
Immatics N.V. (NASDAQ: IMTX) a publié ses résultats financiers du deuxième trimestre 2024 et a fourni une mise à jour sur ses activités. Les principaux faits saillants incluent :
- ACTengine® IMA203 ciblant PRAME a montré un taux de réponse objective confirmée de 55 % chez 30 patients atteints de mélanome métastatique, avec une durée médiane de réponse de 13,5 mois.
- Les premières données de la phase 1 de TCER® IMA401 (MAGEA4/8) seront présentées au Congrès ESMO 2024.
- Une position de liquidités de 568,5 millions de dollars au 30 juin 2024, finançant les opérations jusqu'en 2027.
- Les revenus du deuxième trimestre 2024 s'élevaient à 20,1 millions de dollars, avec une perte nette de 19,3 millions de dollars.
- Nommer Alise Reicin M.D. au Conseil d'administration.
Immatics N.V. (NASDAQ: IMTX) hat ihre Finanzzahlen für das zweite Quartal 2024 veröffentlicht und ein Unternehmensupdate gegeben. Die wichtigsten Highlights sind:
- ACTengine® IMA203, das auf PRAME abzielt, zeigte eine bestätigte objektive Ansprechrate von 55% bei 30 Patienten mit metastasierendem Melanom, mit einer medianen Ansprechdauer von 13,5 Monaten.
- Erste Phase 1-Daten zu TCER® IMA401 (MAGEA4/8) werden auf dem ESMO Kongress 2024 präsentiert.
- Eine Barmittelposition von 568,5 Millionen Dollar zum 30. Juni 2024, die den Betrieb bis 2027 finanziert.
- Die Umsätze im 2. Quartal 2024 betrugen 20,1 Millionen Dollar, bei einem Nettoverlust von 19,3 Millionen Dollar.
- Ernennung von Alise Reicin M.D. in den Vorstand.
- ACTengine® IMA203 showed 55% confirmed objective response rate in metastatic melanoma patients
- Median duration of response for IMA203 was 13.5 months
- Strong cash position of $568.5 million, funding operations into 2027
- Upcoming presentation of first Phase 1 data for TCER® IMA401 at ESMO Congress 2024
- Expansion of clinical footprint outside of melanoma, focusing on ovarian and uterine cancers
- Revenue decreased from $24.0 million in Q2 2023 to $20.1 million in Q2 2024
- Net loss of $19.3 million in Q2 2024
- Increased R&D expenses from $29.2 million in Q2 2023 to $37.7 million in Q2 2024
Insights
Immatics' Q2 2024 results reveal a strong financial position with
The company's focus on TCR-based therapies, particularly in solid tumors, positions them well in a high-potential market. The 55% confirmed objective response rate for IMA203 in melanoma patients is promising, potentially leading to a registration-enabling trial. Upcoming data presentations for IMA401 and IMA402 could be significant catalysts for the stock. Investors should closely monitor these clinical milestones as they could substantially impact Immatics' market valuation.
The clinical data for ACTengine® IMA203 targeting PRAME in metastatic melanoma is highly encouraging. A 55% confirmed objective response rate in heavily pre-treated patients is remarkable, especially considering the 13.5-month median duration of response. The favorable tolerability profile adds to its potential as a viable treatment option. The expansion into ovarian and uterine cancers broadens the therapy's potential impact.
The upcoming TCER® data, particularly IMA401 targeting MAGEA4/8, could be groundbreaking. The high target density approach (>5x higher than competitors) may translate to superior efficacy. The focus on optimizing dosing schedules could improve patient convenience, a important factor in treatment adherence. The diversification of targets (PRAME, MAGEA4/8) across multiple solid tumors demonstrates a robust pipeline strategy, potentially addressing a wide range of hard-to-treat cancers.
Immatics is strategically positioning itself in the competitive immuno-oncology landscape. The company's focus on solid tumors, particularly melanoma, ovarian and uterine cancers, targets areas of high unmet medical need. The planned registration-enabling trial for IMA203 in 2L+ melanoma could accelerate the path to market.
The appointment of Dr. Alise Reicin to the board adds valuable expertise in clinical development, particularly given her experience with Keytruda®. This could enhance Immatics' ability to navigate late-stage trials and potential commercialization. The company's cash runway into 2027 provides a solid foundation for executing its clinical and strategic plans without immediate financing concerns. Upcoming data presentations at ESMO and other conferences in 2H 2024 could significantly impact investor sentiment and potentially attract partnership interest from larger pharmaceutical companies.
- Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D:
55% confirmed objective response rate, median duration of response of 13.5 months; IMA203 continues to maintain a favorable tolerability profile - Registration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 in 2L+ melanoma planned to commence in 2024
- Next data update on IMA203 and IMA203CD8 (GEN2) to be presented at medical conferences in 2H 2024
- First Phase 1 dose escalation clinical data from Immatics’ next-generation, half-life extended TCR Bispecific, TCER® IMA401 (MAGEA4/8), to be presented as an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024
- First next-generation, half-life extended TCER® IMA402 (PRAME) dose escalation data to be announced later in 2H 2024
- Appointment of Alise Reicin M.D. to Board of Directors
- Cash and cash equivalents as well as other financial assets amount to
$568.5 million 1 (€531.1 million ) as of June 30, 2024, funding company operations into 2027
Houston, Texas and Tuebingen, Germany, August 13, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended June 30, 2024.
“It is an exciting time for Immatics as we prepare to reach several major clinical milestones in the second half of the year. Starting with the presentation of the first clinical data on our TCR Bispecific, TCER® IMA401, at ESMO, followed by further data updates from our cell therapy pipeline and the initiation of the IMA203 registration-enabling clinical trial, we look forward to the continued advancement of our product candidates in the coming months,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics. “Patients with advanced solid tumors are in need of transformative therapies that make a meaningful difference in their quality of life. With each clinical milestone we reach, we move one step closer to making an impact in the lives of these patients.”
Second Quarter 2024 and Subsequent Company Progress
ACTengine® Cell Therapy Program
ACTengine® IMA203 and IMA203CD8 (GEN2) monotherapy
On May 14, 2024, Immatics provided a data update on IMA203 monotherapy targeting PRAME from the ongoing Phase 1 trial at the recommended Phase 2 dose (RP2D, 1 to 10 billion total TCR-T cells) in 30 heavily pretreated metastatic melanoma patients evaluable for efficacy.
As of the data cut-off on April 25, 2024, treatment with IMA203 monotherapy in the efficacy population has demonstrated a confirmed objective response rate (cORR) of
Median duration of response (mDOR) was 13.5 months (min 1.2+, max 21.5+ months) including 11 of 16 confirmed objective responses ongoing at data cut-off and longest duration of response ongoing at >21 months after infusion.
Confirmed response rates are similar across all melanoma subtypes (
The next data update, which will include translational and clinical data for IMA203, as well as further details on the clinical trial design for the planned IMA203 Phase 2/3 study, will be presented in 2H 2024 at a medical conference.
Immatics is continuing dose escalation of IMA203CD8 (GEN2) with the goal of defining the optimal dose for further development. The next data update for IMA203CD8 (GEN2) is planned for 2H 2024 with a focus on continued dose escalation data in melanoma patients. In addition to treating melanoma patients, Immatics has also started to expand its clinical footprint outside of melanoma to address a broader patient population with a particular focus on ovarian and uterine cancers.
Immatics’ T cell engaging receptor (TCER®) candidates are next-generation, half-life extended TCR Bispecific molecules. They are designed to maximize efficacy while minimizing toxicities and provide a patient-convenient dosing schedule through the proprietary format consisting of a high-affinity TCR domain against the tumor target and a low-affinity T cell recruiter binding to the T cell.
Upcoming milestones for Immatics’ clinical TCER® pipeline
Martin Wermke, M.D. will present the first clinical data from Immatics’ IMA401 (MAGEA4/8) at the ESMO Congress during an oral presentation titled, Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation, on September 16, 2024, at 11:25 CEST.
Data from approximately 30 patients from the dose escalation phase will be presented. Key objectives include: (1) Demonstrating tolerability of the novel, next-generation, half-life extended TCR Bispecifics format; (2) optimizing dosing schedule to a less frequent regimen during dose escalation, based on pharmacokinetics data; and (3) demonstrating initial clinical anti-tumor activity.
IMA402 (PRAME) data are planned to be announced later in 2H 2024 and will include data from at least 15 patients in early stages of dose escalation across multiple solid cancers, but initially focused on melanoma.
TCER® IMA401 (MAGEA4/8)
The Phase 1 dose escalation basket trial to evaluate safety, tolerability and initial anti-tumor activity of TCER® IMA401 in patients with recurrent and/or refractory solid tumors is ongoing. IMA401 targets an HLA-A*02:01-presented peptide that occurs identically in two different proteins, MAGEA4 and MAGEA8. This target peptide has been selected based on natural expression in native solid tumors at particularly high target density (peptide copy number per tumor cell identified by Immatics’ proprietary quantitative mass spectrometry engine XPRESIDENT® is >5x higher than for a MAGEA4 peptide target used in other clinical trials). MAGEA4 and MAGEA8 are expressed in multiple solid cancers including lung cancer, head and neck cancer, melanoma, ovarian cancer, sarcoma and others.
IMA401 is being developed in collaboration with Bristol Myers Squibb.
TCER® IMA402 (PRAME)
Immatics initiated the Phase 1/2 trial investigating the Company’s fully owned TCER® candidate IMA402 in patients with recurrent and/or refractory solid tumors in August 2023. Initial focus indications are ovarian cancer, lung cancer, uterine cancer and cutaneous and uveal melanoma, among others. IMA402 targets an HLA-A*02:01-presented peptide derived from the tumor antigen PRAME. This target peptide has been selected based on natural expression in native solid primary tumors and metastases at particularly high target density (peptide copy number per tumor cell identified by Immatics’ proprietary quantitative mass spectrometry engine XPRESIDENT®).
Corporate Development
In July 2024, Alise Reicin, M.D., was appointed to Immatics’ Board of Directors as the Company is advancing its pipeline of TCR-based cell therapy and bispecific product candidates into the next phase of development. Dr. Reicin brings extensive experience in early- and late-stage clinical development and has led the successful development of multiple important new therapies, including Keytruda®.
Second Quarter 2024 Financial Results
Cash Position: Cash and cash equivalents as well as other financial assets total
Revenue: Total revenue, consisting of revenue from collaboration agreements, was
Research and Development Expenses: R&D expenses were
General and Administrative Expenses: G&A expenses were
Net Profit and Loss: Net loss was
Full financial statements can be found in the 6-K filed with the Securities and Exchange Commission (SEC) on August 13, 2024, and published on the SEC website under www.sec.gov.
Upcoming Investor Conferences
Jefferies London Healthcare Conference, London, United Kingdom – November 19 – 21, 2024
To see the full list of events and presentations, visit www.investors.immatics.com/events-presentations.
- END -
About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on X, Instagram and LinkedIn.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND or CTA filing for pre-clinical stage product candidates, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.
For more information, please contact:
| Media | |
| Trophic Communications | |
| Phone: +49 171 3512733 | |
| immatics@trophic.eu |
| Immatics N.V. | |
| Jordan Silverstein | |
| Head of Strategy | |
| Phone: +1 346 319-3325 | |
| InvestorRelations@immatics.com |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Loss of Immatics N.V.
| Three months ended June 30, | Six months ended June 30, | |||
| 2024 | 2023 | 2024 | 2023 | |
| (Euros in thousands, except per share data) | (Euros in thousands, except per share data) | |||
| Revenue from collaboration agreements | 18,755 | 22,354 | 49,024 | 32,150 |
| Research and development expenses | (35,216) | (27,317) | (67,324) | (54,898) |
| General and administrative expenses | (10,128) | (9,358) | (21,770) | (18,944) |
| Other income | 25 | 6 | 37 | 948 |
| Operating result | (26,564) | (14,315) | (40,033) | (40,744) |
| Change in fair value of liabilities for warrants | (648) | (13,105) | 395 | (5,708) |
| Other financial income | 9,665 | 3,954 | 20,580 | 6,748 |
| Other financial expenses | (305) | (1,144) | (515) | (4,653) |
| Financial result | 8,712 | (10,295) | 20,460 | (3,613) |
| Loss before taxes | (17,852) | (24,610) | (19,573) | (44,357) |
| Taxes on income | (170) | — | (1,503) | — |
| Net loss | (18,022) | (24,610) | (21,076) | (44,357) |
| Net loss per share: | ||||
| Basic | (0.17) | (0.32) | (0.21) | (0.58) |
| Diluted | (0.17) | (0.32) | (0.21) | (0.58) |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Comprehensive Loss of Immatics N.V.
| Three months ended June 30, | Six months ended June 30, | |||
| 2024 | 2023 | 2024 | 2023 | |
| (Euros in thousands) | (Euros in thousands) | |||
| Net loss | (18,022) | (24,610) | (21,076) | (44,357) |
| Other comprehensive income | ||||
| Items that may be reclassified subsequently to profit or loss | ||||
| Currency translation differences from foreign operations | 462 | (224) | 798 | 340 |
| Total comprehensive loss for the year | (17,560) | (24,834) | (20,278) | (44,017) |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Financial Position of Immatics N.V.
| As of | ||
| June 30, 2024 | December 31, 2023 | |
| (Euros in thousands) | ||
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | 158,143 | 218,472 |
| Other financial assets | 372,964 | 207,423 |
| Accounts receivables | 2,811 | 4,093 |
| Other current assets | 25,200 | 19,382 |
| Total current assets | 559,118 | 449,370 |
| Non-current assets | ||
| Property, plant and equipment | 50,289 | 43,747 |
| Intangible assets | 1,608 | 1,523 |
| Right-of-use assets | 14,616 | 13,308 |
| Other non-current assets | 1,336 | 2,017 |
| Total non-current assets | 67,849 | 60,595 |
| Total assets | 626,967 | 509,965 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Provisions | 3,437 | — |
| Accounts payables | 18,791 | 25,206 |
| Deferred revenue | 95,521 | 100,401 |
| Liabilities for warrants | 18,598 | 18,993 |
| Lease liabilities | 3,178 | 2,604 |
| Other current liabilities | 10,021 | 9,348 |
| Total current liabilities | 149,546 | 156,552 |
| Non-current liabilities | ||
| Deferred revenue | 75,298 | 115,527 |
| Lease liabilities | 14,235 | 12,798 |
| Other non-current liabilities | — | 4 |
| Total non-current liabilities | 89,533 | 128,329 |
| Shareholders’ equity | ||
| Share capital | 1,031 | 847 |
| Share premium | 1,006,064 | 823,166 |
| Accumulated deficit | (618,369) | (597,293) |
| Other reserves | (838) | (1,636) |
| Total shareholders’ equity | 387,888 | 225,084 |
| Total liabilities and shareholders’ equity | 626,967 | 509,965 |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Cash Flows of Immatics N.V.
| Six months ended June 30, | ||
| 2024 | 2023 | |
| (Euros in thousands) | ||
| Cash flows from operating activities | ||
| Net loss | (21,076) | (44,357) |
| Taxes on income | 1,503 | — |
| Loss before tax | (19,573) | (44,357) |
| Adjustments for: | ||
| Interest income | (12,660) | (4,999) |
| Depreciation and amortization | 6,116 | 3,666 |
| Interest expenses | 420 | 401 |
| Equity-settled share-based payment | 8,605 | 11,615 |
| Loss from disposal of fixed assets | 1 | |
| Net foreign exchange differences and expected credit losses | (7,723) | 4,081 |
| Change in fair value of liabilities for warrants | (395) | 5,708 |
| Changes in: | ||
| Decrease in accounts receivables | 1,283 | 781 |
| Decrease/(increase) in other assets | (1,246) | 765 |
| (Decrease) in deferred revenue, accounts payables and other liabilities | (48,493) | (9,889) |
| Interest received | 8,260 | 2,051 |
| Interest paid | (420) | (146) |
| Income tax paid | — | — |
| Net cash used in operating activities | (65,825) | (30,323) |
| Cash flows from investing activities | ||
| Payments for property, plant and equipment | (11,797) | (15,004) |
| Payments for intangible assets | (148) | (154) |
| Payments for investments classified in other financial assets | (356,596) | (170,326) |
| Proceeds from maturity of investments classified in other financial assets | 196,548 | 164,929 |
| — | — | |
| Net cash used in investing activities | (171,993) | (20,555) |
| Cash flows from financing activities | ||
| Proceeds from issuance of shares to equity holders | 174,476 | 38,608 |
| Transaction costs deducted from equity | (1,157) | |
| Repayments related to lease liabilities | (397) | (1,866) |
| Net cash provided by financing activities | 174,079 | 35,585 |
| Net decrease in cash and cash equivalents | (63,739) | (15,293) |
| Cash and cash equivalents at beginning of the year | 218,472 | 148,519 |
| Effects of exchange rate changes and expected credit losses on cash and cash equivalents | 3,410 | (2,821) |
| Cash and cash equivalents at end of the year | 158,143 | 130,405 |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Changes in Shareholders’ Equity of Immatics N.V.
| (Euros in thousands) | Share capital | Share premium | Accumulated deficit | Other reserves | Total share- holders’ equity |
| Balance as of January 1, 2023 | 767 | 714,177 | (500,299) | (1,481) | 213,164 |
| Other comprehensive income | — | — | — | 340 | 340 |
| Net loss | — | — | (44,357) | — | (44,357) |
| Comprehensive loss for the year | — | — | (44,357) | 340 | (44,017) |
| Equity-settled share-based compensation | — | 11,615 | — | — | 11,615 |
| Share options exercised | — | 40 | — | — | 40 |
| Issue of share capital – net of transaction costs | 37 | 37,374 | — | — | 37,411 |
| Balance as of June 30, 2023 | 804 | 763,206 | (544,656) | (1,141) | 218,213 |
| Balance as of January 1, 2024 | 847 | 823,166 | (597,293) | (1,636) | 225,084 |
| Other comprehensive income | — | — | — | 798 | 798 |
| Net loss | — | — | (21,076) | — | (21,076) |
| Comprehensive loss for the year | — | — | (21,076) | 798 | (20,278) |
| Equity-settled share-based compensation | — | 8,605 | — | — | 8,605 |
| Share options exercised | 1 | 1,036 | — | — | 1,037 |
| Issue of share capital – net of transaction costs | 183 | 173,257 | — | — | 173,440 |
| Balance as of June 30, 2024 | 1,031 | 1,006,064 | (618,369) | (838) | 387,888 |
1 All amounts translated using the exchange rate published by the European Central Bank in effect as of June 30, 2024 (1 EUR = 1.0705 USD).
Attachment
FAQ
What was Immatics' (IMTX) confirmed objective response rate for ACTengine® IMA203 in metastatic melanoma patients?
When will Immatics (IMTX) present the first Phase 1 data for TCER® IMA401?
What was Immatics' (IMTX) cash position as of June 30, 2024?
How much revenue did Immatics (IMTX) generate in Q2 2024?
